News

Scripps Research scientists and collaborators use an innovative set of machine-learning models to discover a record-breaking material for film capacitors, key components in many energy technologies.

New findings underscore the importance of ongoing surveillance for H5N1 mutations that pose risks to public health.

Funding from ARPA-H will be used to develop a vaccine for alphaviruses in preparation of major outbreaks in the U.S.

Technologies developed by both teams will map the human eye-brain connectome, extend the lifespan of the revived human eye, and help regenerate and monitor the optic nerve after a whole eye transplant.

Featured scientists represent a wide range of fields including chemistry, microbiology, immunology, neuroscience and more

Scripps Research scientists improved existing vaccines by analyzing the molecular structure and stability of viral proteins.

Scripps Research has added Benjamin Cravatt, PhD, professor of Chemistry and the Norton B. Gilula Chair in Biology and Chemistry at Scripps Research, and Lou Lange, MD, PhD, physician-scientist and general partner with Asset Management Ventures, to its Board of Directors.

By examining RNA in hundreds of thousands of individual brain cells, Scripps Research scientists further support that alcohol use disorder could accelerate Alzheimer’s disease progression, paving the way for future targeted treatments.

CMR316 is a once-weekly inhaled, lung-targeted drug designed to precisely expand lung stem cells and regenerate damaged lung tissue. 

Scientists at Scripps Research and its drug discovery arm, Calibr-Skaggs, develop first-in-class small molecules to repair damaged tissues of the heart, lungs, joints, and more.  

By creating personalized brain “organoids” in the lab, Scripps Research scientists showed how microRNAs impact brain development, and demonstrate how one drug can reverse critical cellular signs of autism.

Scripps Research scientists show that alcohol withdrawal causes long-lasting sensitivity to mechanical stimuli in heavy drinkers, and identify a drug target that could help.

Scientists uncover how small molecules interact with a cancer-related protein called FOXA1 and identify a crucial binding site on its surface.

The two distinct awards will support collaborative research projects into pollution’s impact on autism as well as risk genes in psychiatric disorders.

Fellows Shannon Miller and Megan Ken have both received NIH Director’s Awards from the NIH Common Fund’s High-Risk, High-Reward Research program.

The grant from the NIA/NIH will support research into how air pollution could lead to the development of Alzheimer’s disease.

Scripps Research scientists used knowledge about a protein to characterize drugs that selectively bind to its “twin,” or paralog.

The awards from the NIDDK and the LLHF will let Droujinine uncover how interorgan communication goes awry in metabolic disease and aging, paving the way for new treatments.

An international collaboration between Scripps Research, University of Arizona, CNRS and others provides additional analysis of how the pandemic began.

The novel method uses sets of four RNA nucleotides—rather than the natural three—to encode new, synthetic building blocks into proteins.

Using a combination of two protein-mapping methods, Scripps Research scientists uncover novel proteins that could be targeted by future cancer drugs.

Scripps Research scientists discovered a molecule produced by roundworm intestines that signals the brain to slow fat loss when food is not available. 

The building blocks can be used to create polymers with previously unexplored structures and fine-tunable properties, with applications across energy storage and more.

Scripps Research scientists showed that, with help from an AI tool, cardiologists can diagnose heart attacks using a simpler, easier and more accessible electrocardiogram technology.